NCT00652457 is a Phase 4 clinical trial of Memantine in Huntington's Disease, sponsored by Jody Corey-Bloom, MD, PhD.

Who is sponsoring NCT00652457?

NCT00652457 is sponsored by Jody Corey-Bloom, MD, PhD.

What drugs are being tested in NCT00652457?

Interventions in NCT00652457: Memantine.

What condition does NCT00652457 study?

NCT00652457 studies Huntington's Disease.

Is NCT00652457 still recruiting?

NCT00652457 is currently completed. Last updated 5 January 2021.

Are results published for NCT00652457?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-01-05 · How we verify

NCT00652457

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Memantine to Treat Huntington's Disease

Completed Phase 4 Results posted Last updated 5 January 2021

What this trial tests

Phase 4 trial testing Memantine in Huntington's Disease in 50 participants. Completed in 28 October 2009.

Timeline

23 November 2004

Primary endpoint
28 October 2009

28 October 2009

Quick facts

Lead sponsor	Jody Corey-Bloom, MD, PhD
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	23 November 2004
Primary completion	28 October 2009
Estimated completion	28 October 2009
Sites	3 locations across United States

Drugs / interventions tested

Memantine (MEMANTINE) — full drug profile →

Conditions studied

Huntington's Disease — all drugs for Huntington's Disease →

Sponsor

Jody Corey-Bloom, MD, PhD

Who can join

18 and older, any sex, with Huntington's Disease. Patients with the condition only — healthy volunteers not accepted.

Adverse events — posted to ClinicalTrials.gov

Time frame: 6 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Memantine, Then Memantine

Serious: 0/23 (0%)

Deaths: 0/23

Placebo, Then Memantine

Serious: 0/27 (0%)

Deaths: 0/27

Other adverse events (2 terms — click to expand)

Reaction	System	Memantine, Then Memantine	Placebo, Then Memantine
Dizziness	Nervous system disorders	—	—
Diarrhea	Gastrointestinal disorders	—	—

Data from ClinicalTrials.gov NCT00652457 adverse events section.

Sponsor's own description

To determine if memantine in doses of 10 mg BID affects memory, cognition, and behavior in patients with Huntington's disease (HD).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Calcium signaling and neurodegenerative diseases.
Bezprozvanny I. · · 2009 · cited 352× · PMID 19230774 · DOI 10.1016/j.molmed.2009.01.001
NMDA receptors in clinical neurology: excitatory times ahead.
Kalia LV, Kalia SK, Salter MW. · · 2008 · cited 307× · PMID 18635022 · DOI 10.1016/s1474-4422(08)70165-0
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.
Jiang A, Handley RR, Lehnert K, Snell RG. · · 2023 · cited 88× · PMID 37629202 · DOI 10.3390/ijms241613021
Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.
Miller BR, Bezprozvanny I. · · 2010 · cited 56× · PMID 21977007 · DOI 10.2217/fnl.10.41
Calcium signaling and neurodegeneration.
Bezprozvanny IB. · · 2010 · cited 53× · PMID 22649630 · DOI 10.32607/20758251-2010-2-1-72-80
Huntington’s Disease Clinical Trials Corner: February 2018
Rodrigues FB, Wild EJ. · · 2018 · cited 45× · PMID 29480210 · DOI 10.3233/jhd-189001
Clinical Trials Corner: September 2017.
Rodrigues FB, Wild EJ. · · 2017 · cited 33× · PMID 28968245 · DOI 10.3233/jhd-170262
Huntington's Disease Clinical Trials Corner: August 2018.
Rodrigues FB, Wild EJ. · · 2018 · cited 22× · PMID 30103342 · DOI 10.3233/jhd-189003

Verify or expand the search:

Other trials of Memantine

Trials testing the same drug.

NCT06727773 — Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemot · Phase 2 · recruiting
NCT06914310 — Memantine as an Additive Therapy in Patients With Traumatic Brain Injury · Phase 2, PHASE3 · not yet recruiting
NCT07417670 — Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease · Phase 4 · completed
NCT05418049 — Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge · Phase 2 · active not recruiting
NCT05013892 — NTS-WBRT in Brain Metastases · Phase 2 · recruiting

Other recruiting trials for Huntington's Disease

Currently open trials in the same condition.

NCT07246941 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease · Phase 1 · recruiting
NCT06585449 — A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease · Phase 1 · recruiting
NCT02855476 — HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00652457 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jody Corey-Bloom, MD, PhD
Last refreshed: 5 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00652457.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing